In pharmaceutical and biotech deals, success stories featuring startups are relatively rare. Israelsen has one to share.
He led the intellectual property legal team for Alios Biopharma in its recent negotiations with Vertex Pharmaceuticals, licensing two Hepatitis C drugs to Vertex in a deal worth up to $1.5 billion.
With so many hard-luck stories about startups burning up their meager resources and ultimately going under, Alios was able to ...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In